CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
-
Father's Day near-miss at US Open brings Burns to tears
-
New coach Rennie names Savea as All Blacks captain
-
Scheffler praises Clark's resolve in gutsy US Open triumph
-
Yamal kickstarts Spain World Cup bid as Cape Verde stun Uruguay
-
Cape Verde fight back for second World Cup draw against Uruguay
-
Mexican fans rally behind Iran as 'our second team' at World Cup
-
Iran-US talks to continue through the night
-
Trump-backed candidate wins razor-tight Colombia presidential election
-
Clark edges Burns by one stroke for second US Open title
-
Iran coach hails 'great achievement' after second World Cup draw
-
Curacao firmly on the map after World Cup heroics
-
Pro-Trump presidential hopeful takes early lead as Colombia counts votes
-
Trump say repairs to begin 'immediately' for Washington pool renovation
-
Yamal off the mark at World Cup in Spain rout as Iran hold Belgium
-
Rune 'not ready' to put a date on tennis return
-
Argentina weaknesses? Austria's World Cup coach can't find any
-
Polls close in Colombia runoff pitting pro-Trump hardliner against leftist
-
A nation divided over Team Melli as Iran faces Belgium
-
McIlroy races for exit after weekend US Open fade
-
Belgium held 0-0 by Iran as Ngoy sent off
-
Mbappe ready for 'special' 100th cap for France at World Cup
-
Watkins ready for England super-sub role at World Cup
-
Yamashita tops Woad in playoff to win Meijer LPGA Classic
-
Clark leads Burns by one as US Open back-nine drama begins
-
Syria president denies wanting to intervene in Lebanon after Trump remarks
-
Timeless Messi eyes World Cup record as Argentina face Austria
-
Saudi critics must be 'realists', says Donis after Spain lesson
-
Brazil must adapt to loss of injured Raphinha at World Cup, says Paqueta
-
Serena Williams given Wimbledon singles wildcard
-
'Absurd' to doubt Spain, says De la Fuente after Saudi Arabia rout
-
Iranians walk out of talks venue after Trump threat
-
Iraq's Arnold promises to have a go against France at World Cup
-
'Toy Story 5' rakes in $160 mn in year's best opening weekend
-
Legendary Cuban spy chief Ramiro Valdes dies at 94
-
Yamal off the mark at World Cup as Spain thrash Saudi Arabia
-
Clark and Scheffler begin final-round drama at US Open
-
Yamal off mark at World Cup as Spain thrash Saudi
-
Yamal scores on injury return as Spain thrash Saudi Arabia
-
Noskova overpowers Pegula to win Berlin WTA
-
Iran warns US to 'be careful' after Trump threat
-
Gakpo savours 'freedom' to fire Dutch in World Cup title bid
-
Cerundolo outlasts Paul to win marathon Queen's Club final
-
Pogacar wins final stage to seal Tour of Switzerland success
-
Henry the hero for New Zealand as England bring back Stokes
-
Bolivia removes roadblocks after emergency decree
-
Vance hopes US, Iran can turn 'new leaf' with talks
-
Europe sweats through new heatwave, with worse to come
-
Trump-backed hardliner faces leftist senator as Colombia votes
-
Japan striker Ueda channels frustration to send World Cup warning
-
Dominant Tiafoe swats aside Fritz to win Halle Open
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
H.Gonzales--AT
